LIGAND PHARMACEUTICALS INC Insider Trading for February 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in LIGAND PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in LIGAND PHARMACEUTICALS INC for February 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 23 2021 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Option Exercise | M | 10.12 | 2,500 | 25,300 | 4,835 | |
| Feb 23 2021 | LGND | LIGAND PHARMACEUTI ... | KOZARICH JOHN W | Director | Buy | M | 10.12 | 2,500 | 25,300 | 29,708 | 27.2 K to 29.7 K (+9.19 %) |
| Feb 12 2021 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Option Exercise | M | 195.91 | 2,474 | 484,681 | 0 | |
| Feb 12 2021 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Buy | M | 195.91 | 2,474 | 484,681 | 50,152 | 47.7 K to 50.2 K (+5.19 %) |
| Feb 12 2021 | LGND | LIGAND PHARMACEUTI ... | Davis Todd C | Director | Sell | S | 213.14 | 5,083 | 1,083,410 | 47,678 | 52.8 K to 47.7 K (-9.63 %) |
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 14.47 | 54,666 | 791,017 | 14,334 | |
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | M | 10.05 | 60,000 | 603,000 | 0 | |
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Payment of Exercise | F | 203.03 | 2,970 | 602,999 | 343,060 | 346 K to 343.1 K (-0.86 %) |
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 10.05 | 60,000 | 603,000 | 346,030 | 286 K to 346 K (+20.98 %) |
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Sell | S | 203.40 | 54,666 | 11,119,239 | 286,030 | 340.7 K to 286 K (-16.05 %) |
| Feb 09 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Buy | M | 14.47 | 54,666 | 791,017 | 340,696 | 286 K to 340.7 K (+19.11 %) |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Option Exercise | A | 177.50 | 6,955 | 1,234,513 | 6,955 | |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Sell | S | 178.50 | 18,097 | 3,230,376 | 28,906 | 47 K to 28.9 K (-38.50 %) |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | Berkman Charles S | SVP, Gen. Counsel & ... | Grant | A | 0.00 | 3,491 | 0 | 47,003 | 43.5 K to 47 K (+8.02 %) |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | A | 177.50 | 13,136 | 2,331,640 | 13,136 | |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | M | 74.42 | 1,000 | 74,420 | 63,210 | |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Option Exercise | M | 21.92 | 44,547 | 976,470 | 20,000 | |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Sell | S | 176.86 | 44,547 | 7,878,582 | 168,198 | 212.7 K to 168.2 K (-20.94 %) |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Buy | M | 21.92 | 44,547 | 976,470 | 212,745 | 168.2 K to 212.7 K (+26.48 %) |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Buy | M | 74.42 | 1,000 | 74,420 | 168,198 | 167.2 K to 168.2 K (+0.60 %) |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | FOEHR MATTHEW W | President and COO | Grant | A | 0.00 | 6,595 | 0 | 167,198 | 160.6 K to 167.2 K (+4.11 %) |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Option Exercise | A | 177.50 | 25,113 | 4,457,558 | 25,113 | |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | HIGGINS JOHN L | Chief Executive Off ... | Grant | A | 0.00 | 12,608 | 0 | 286,030 | 273.4 K to 286 K (+4.61 %) |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Option Exercise | A | 177.50 | 11,591 | 2,057,403 | 11,591 | |
| Feb 05 2021 | LGND | LIGAND PHARMACEUTI ... | Korenberg Matthew E | EVP,Finance & Strat ... | Grant | A | 0.00 | 10,819 | 0 | 41,752 | 30.9 K to 41.8 K (+34.98 %) |